#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glomerulonephritis chronic Cystic fibrosis gastrointestinal disease Necrotising myositis Retinopathy proliferative Myotonic dystrophy Breast angiosarcoma metastatic Chronic kidney disease Ischaemic stroke Colorectal cancer metastatic Hypersomnia Autoimmune haemolytic anaemia Small cell lung cancer extensive stage Dedifferentiated liposarcoma Waldenstrom's macroglobulinaemia recurrent Proteus syndrome More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma Haemophagocytic lymphohistiocytosis – Diagnostics Glomerulonephritis membranous Hairy cell leukaemia recurrent – Life with Disease Leiomyosarcoma – Basic Information Chordoma – Diagnostics Mantle cell lymphoma stage IV Mitochondrial myopathy – Life with Disease Choroid melanoma – Basic Information Glycogen storage disease type I – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ramipril Cobolimab Trastuzumab TRIACYLGLYCEROL LIPASE Vamorolone Donanemab Fenofibrate VAMIFEPORT TRIHYDROCHLORIDE Doxazosin Allo-501A L-PROLINE [18F]CPFPX Treosulfan Sodium Phosphate Pentixafor Gallium Ga-68 Epinephrine Hydrochloride Tamoxifen Citrate Mebendazole Buclizine Hydrochloride CYCLIZINE HYDROCHLORIDE More therapies…

    Learn about Your Condition

    Leiomyosarcoma metastatic Labour pain Substance use disorder Hereditary angioedema Pancreatitis relapsing Cholecystitis acute Follicular lymphoma Hodgkin's disease recurrent Systemic infection Ewing's sarcoma BRAF gene mutation Laparotomy Colon cancer stage II Growth hormone deficiency Hypopituitarism More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2wy Bazvzhfne Du Sgqzro Midilzkvovc Bc 1aaw Mwpykjitrj 1aohqe Fzlnvv

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Fulvestrant
    France

  • Study of Pemigatinib for Patients with Recurrent or Metastatic Solid Tumors with FGFR Gene Alteration

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Pemigatinib
    France

  • Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    • Endometrial cancer
    • Ovarian cancer
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    France Italy Spain

  • Study of Pembrolizumab and Cabozantinib for Patients with Advanced Sarcomas: Undifferentiated Pleomorphic Sarcoma, Osteosarcoma, and Ewing Sarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Sarcoma
    • Malignant fibrous histiocytoma
    • Osteosarcoma
    Investigated Drugs:
    • Cabozantinib
    • Pembrolizumab
    France

  • Study on Durvalumab and Tremelimumab for Patients with Kidney Cancer at Risk of Recurrence After Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Durvalumab
    • Tremelimumab
    France Spain

  • Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Pertuzumab
    • Trastuzumab
    • Trastuzumab Deruxtecan
    France

  • Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Cisplatin
    • Etoposide
    • Fluorouracil
    France

  • Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Lymphocytic leukaemia
    • Acute lymphocytic leukaemia
    Investigated Drugs:
    • Blinatumomab
    • Isatuximab
    • Ponatinib
    Belgium France

  • A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Ductal adenocarcinoma of pancreas
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    France Germany Italy Spain

  • A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Capecitabine
    Austria Belgium Czechia France Germany Italy +5
Previous Page
1 … 15 16 17 18 19 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!